|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Congenital heart block (CHB) may develop in fetuses of Ro/SSA autoantibody-positive women.
|
30808622 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measurement of anti-Ro52 antibody levels may be helpful in extracting a risk group of delivering CHB infants in the anti-Ro/SSA antibody positive pregnancy.
|
28880700 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed occurrence of postnatal DCM among children with high-degree congenital heart block (CHB) and mothers with anti-SSA and/or anti-SSB antibodies.
|
28843719 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
High expression of SIGLEC1 in pregnant women with autoantibodies against Ro/SS-A indicates an enhanced risk for CHB development, and these women may benefit especially from IFN-α directed therapy, for example with hydroxychloroquine.
|
28501799 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The signature lesion of SSA/Ro autoantibody-associated congenital heart block (CHB) is fibrosis and a macrophage infiltrate, supporting an experimental focus on cues influencing the fibroblast component.
|
28626076 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Congenital heart block (CHB) is an autoantibody mediated disorder presumably caused by placental transmission of maternal autoantibodies to Ro/SSA 52 kd, p200, Ro/SSA 60 kd, La/SSB ribonucleoproteins.
|
28204891 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only 2% of mothers positive for anti-SSA/Ro (Ro) antibodies have children with congenital heart block (CHB).
|
25994441 |
2015 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA-DRB1*04 and HLA-Cw*05 were identified as novel foetal HLA allele variants that confer susceptibility to CHB in response to Ro/SSA autoantibody exposure, whilst DRB1*13 and Cw*06 emerged as protective alleles.
|
24354957 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we observed that CHB can develop in a genetically unrelated child exposed in utero to anti-SSA/Ro antibodies.
|
20499382 |
2010 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recently reported that maternal sera containing antibodies against SSA/Ro and SSB/La ribonucleoproteins (positive IgG) inhibited L-type Ca current in isolated cardiac myocytes and induced sinus bradycardia in a murine model of CHB.
|
11257091 |
2001 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although a strong clinical association exists between congenital heart block (CHB) and an immune response to SSA/Ro and SSB/La proteins, a causative role of these antibodies in the pathogenesis is just emerging.
|
9667364 |
1998 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conversely, maternal HLA-DQB1*0602 carried on HLA-DR2 haplotypes was associated with CHB but not cutaneous NLE; (ii) HLA-DQA1 alleles with glutamine at position 34 of the first domain, which have reportedly been associated with the autoimmune responses to Ro/SSA antigens in other ethnic groups, were increased in the mothers of infants with cutaneous involvement; and (iii) there was no particular class II HLA profile that distinguished the disease manifestations in infants.
|
9182815 |
1997 |
|
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We recently described an alternatively spliced 52-kd SS-A/Ro messenger RNA (mRNA) derived from the skipping of exon 4 which encodes a smaller protein, 52beta (MW 45 kd), recognized by CHB maternal antisera.
|
9125247 |
1997 |